icon-folder.gif   Conference Reports for NATAP  
 
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
 
 
 
A MULTICENTER STUDY OF PROTEASE INHIBITOR-TRIPLE THERAPY IN HCV-INFECTED LIVER TRANSPLANT RECIPIENTS: REPORT FROM THE CRUSH-C GROUP
 
 
  Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
 
E.C. Verna1*, J.R. Burton2, J.G. O'Leary3, J.C. Lai4, V. Saxena4, J.L. Dodge4, G.T. Everson2, J.F. Trotter3, R.T. Stravitz5, R.S. Brown, Jr.1, N.A. Terrault4, CRUSH-C
1Columbia University College of Physicians and Surgeons, New York, NY, 2University of Colorado, Denver, CO, 3Baylor University Medical Center, Dallas, TX, 4University of California San Francisco, San Francisco, CA, 5Virginia Commonwealth University, Richmond, VA, USA
 
EASL: End Of Treatment Response After Protease Inhibitor-based Therapy For Hepatitis C Recurrence After Liver Transplantation: A Multicentric European Experience - (05/03/13)
 
EASL: PHARMACOKINETIC INTERACTIONS BETWEEN THE HCV PROTEASE INHIBITOR BOCEPREVIR AND SIROLIMUS IN HEALTHY SUBJECTS - (05/06/13)

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif